PROFILPELAJAR.COM

K252a
Names
	Preferred IUPAC name Methyl (13S,14R,16R)-14-hydroxy-13-methyl-5-oxo-6,7,13,14,15,16-hexahydro-5H-13,16-epoxydiindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-14-carboxylate
Identifiers
CAS Number	99533-80-9 ;
ChEMBL	ChEMBL281948 ;
ChemSpider	2299962 ;
ECHA InfoCard	100.167.781
IUPHAR/BPS	336;
PubChem CID	3035817;
UNII	IV7H45AM5B ;
CompTox Dashboard (EPA)	DTXSID40880065 ;
	InChI InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18?,26-,27-/m1/s1 Key: KOZFSFOOLUUIGY-CYBHFKQVSA-N ;
Properties
Chemical formula	C27H21N3O5
Molar mass	467.481 g·mol−1
Solubility in other solvents	Soluble in DMSO, dichloromethane, and methanol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

K252a is an alkaloid isolated from Nocardiopsis bacteria. This staurosporine analog is a highly potent cell permeable inhibitor of CaM kinase and phosphorylase kinase (IC₅₀ = 1.8 and 1.7 nmol/L, respectively). At higher concentrations it is also an efficient inhibitor of serine/threonine protein kinases (IC₅₀ of 10 to 30 nmol/L).^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

K252a is reported to promote myogenic differentiation in C2 mouse myoblasts^[6] and has been shown to block the neuronal differentiation of rat pheochromocytoma PC12 cells by inhibition of trk tyrosine kinase activity.^[10]

K252a has been reported in preclinical research as a potential treatment for psoriasis.^[11]

K252a inhibits tyrosine phosphorylation of Trk A induced by NGF. PC12 cells were incubated in the presence or absence of 10 ng/ml NGF with or without various concentrations of K252a.

References

^ K252a from Fermentek
^ Ruegg, U.T. et al. (1989) Tips 10, 218.
^ Eliot, L.H. et al. (1990) B.B.R.C. 171, 148.
^ Simpson, D.l. et al. (1991) J. Neurosci. Res, 28, 148.
^ Chin, L.S. et al. (1999) Cancer Invest. 17, 391.
^ ^a ^b Tapley, P. et al. (1992) Oncogene 7, 371.
^ Hashimoto, S. (1998) J. Cell Biol. 107, 1531.
^ Kase, H. et al. (1987) B.B.R.C. 142, 436.
^ Hirayama E. et al. (2001) B.B.R.C. 285, 1237.
^ Borasio, G.D. Neurosci. Lett. (1990) 108, 207.
^ Dubois Declercq, Sarah; Pouliot, Roxane (2013). "Promising New Treatments for Psoriasis". The Scientific World Journal. doi:10.1155/2013/980419. PMC 3713318. PMID 23935446.